Neurological complications associated with anti–programmed death 1 (PD-1) antibodies

JAMA Neurology

Volumn 74, Issue 10, 2017, Pages 1216-1222

  Kao, Justin C ^a   Liao, Bing ^a   Markovic, Svetomir N ^a   Klein, Christopher J ^a   Naddaf, Elie ^a   Staff, Nathan P ^a   Liewluck, Teerin ^a   Hammack, Julie E ^a   Sandroni, Paola ^a   Finnes, Heidi ^a   Mauermann, Michelle L ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; IMMUNOGLOBULIN; METHYLPREDNISOLONE; NIVOLUMAB; PEMBROLIZUMAB; PREDNISONE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR;

ADULT; AGED; ARTICLE; ASYMMETRIC VASCULITIC NEUROPATHY; AUTOIMMUNE RETINOPATHY; AXONAL THORACOLUMBAR POLYRADICULOPATHY; BILATERAL INTERNUCLEAR OPHTHALMOPLEGIA; CEREBELLAR ATAXIA; COHORT ANALYSIS; COLITIS; DEMYELINATING POLYRADICULO NEUROPATHY; DISABILITY; DISEASE SEVERITY; DYSARTHRIA; ESOPHAGEAL ADENOCARCINOMA; FEMALE; HEADACHE; HEPATITIS; HUMAN; HYPOTHYROIDISM; LEIOMYOSARCOMA; LENGTH DEPENDENT NEUROPATHY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MELANOMA; MYOPATHY; NECROTIZING MYOPATHY; NEUROLOGIC DISEASE; NEUROLOGICAL COMPLICATION; NEUROPATHY; OPHTHALMOPLEGIA; PERITONEUM MESOTHELIOMA; PLASMA EXCHANGE; PRIORITY JOURNAL; RANKIN SCALE; RETINOPATHY; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; CHEMICALLY INDUCED; ELECTROMYOGRAPHY; IMMUNOLOGY; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM DISEASES;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; ELECTROMYOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NERVOUS SYSTEM DISEASES; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 85031757174     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2017.1912     Document Type: Article

References (22)

1. Zimmer L, Goldinger SM, Hofmann L, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti–PD-1 therapy. Eur J Cancer. 2016;60:210-225.
2. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264.
3. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci Transl Med. 2014;6(230):230ra45.
4. Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39.
5. Robert C, Schachter J, Long GV, et al; KEYNOTE-006 Investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372(26):2521-2532.
6. Seiwert TY, Burtness B, Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7): 956-965.
7. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti–PD-1 and anti–PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26(12):2375-2391.
8. Marrone KA, Ying W, Naidoo J. Immune-related adverse events from immune checkpoint inhibitors. Clin Pharmacol Ther. 2016;100(3):242-251.
9. Lau KH, Kumar A, Yang IH, Nowak RJ. Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab. Muscle Nerve. 2016;54(1):157-161.
10. Polat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with non–small-cell lung cancer. Muscle Nerve. 2016;54(3):507.
11. Sciacca G, Nicoletti A, Rampello L, Noto L, Parra HJ, Zappia M. Benign form of myasthenia gravis after nivolumab treatment. Muscle Nerve. 2016;54 (3):507-509.
12. Vallet H, Gaillet A, Weiss N, et al. Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma. Ann Oncol. 2016;27(7):1352-1353.
13. Haddox CL, Shenoy N, Shah KK, et al. Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm. Ann Oncol. 2017;28(3):673-675.
14. Aya F, Ruiz-Esquide V, Viladot M, et al. Vasculitic neuropathy induced by pembrolizumab. Ann Oncol. 2017;28(2):433-434.
15. de Maleissye MF, Nicolas G, Saiag P. Pembrolizumab-induced demyelinating polyradiculoneuropathy. N Engl J Med. 2016;375(3):296-297.
16. Tanaka R, Maruyama H, Tomidokoro Y, et al. Nivolumab-induced chronic inflammatory demyelinating polyradiculoneuropathy mimicking rapid-onset Guillain-Barré syndrome: a case report. Jpn J Clin Oncol. 2016;46(9):875-878.
17. Mandel JJ, Olar A, Aldape KD, Tremont-Lukats IW. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci. 2014;344(1-2):229-231.
18. Salam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep. 2016;2016: bcr2016215012.
19. Roberts P, Fishman GA, Joshi K, Jampol LM. Chorioretinal lesions in a case of melanoma-associated retinopathy treated with pembrolizumab. JAMA Ophthalmol. 2016;134(10):1184-1188.
20. Banks JL, Marotta CA. Outcomes validity and reliability of the modified Rankin Scale: implications for stroke clinical trials: a literature review and synthesis. Stroke. 2007;38(3):1091-1096.
21. Highlights of prescribing information. OPDIVO(R) (nivolumab) injection, for intravenous use. https://packageinserts.bms.com/pi/pi_opdivo.pdf. Initial US approval 2014. Accessed July 18, 2017.
22. D’Aoust J, Hudson M, Tatibouet S, et al; Canadian Scleroderma Research Group. Clinical and serologic correlates of anti-PM/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients. Arthritis Rheumatol. 2014;66(6): 1608-1615.